Curated by THEOUTPOST
On Tue, 23 Jul, 8:00 AM UTC
2 Sources
[1]
QDX Announces Collaboration with Prelude Therapeutics on Novel Oncology Programs | Taiwan News | Jul. 23, 2024 08:00
SINGAPORE, July 23, 2024 /PRNewswire/ -- QDX, a computational drug discovery company, today announced a collaboration with Prelude Therapeutics, a clinical-stage precision oncology company, targeting undisclosed, previously undrugged oncology targets. QDX integrates its world-leading quantum mechanical simulation technology, supercomputing, artificial intelligence, and deep drug discovery expertise to advance computational chemistry and drug discovery. Peggy Scherle, PhD, CSO of Prelude, commented: "Computational approaches to drug discovery are showing increasing promise. We are pleased to work with the talented team at QDX to leverage their blend of high-performance computing, quantum simulations, and AI on these historically challenging targets." Loong Wang, Co-Founder and CEO of QDX, stated: "We are thrilled to be working with the team at Prelude to help break new ground on these programs. This collaboration with Prelude exemplifies the kind of bespoke partnerships that QDX engages in across academia and industry, deploying our best-in-class quantum technology, our massively parallel supercomputing, and AI systems." Kelvin Neu, MD, Co-Founder and Chair of QDX, added: "The accomplished biology and chemistry teams at Prelude have been very productive, generating a pipeline of small molecules against important and often challenging oncology targets. QDX has built a powerful platform by thoughtfully integrating complementary disciplines, guided by the practical needs and challenges of novel drug discovery, with a particular focus on select traditionally difficult-to-crack areas. We are honored that Prelude has chosen QDX to support them on these challenging targets and look forward to a productive collaboration." About QDX QDX is a computational drug discovery company integrating quantum mechanical simulations, supercomputing, and artificial intelligence. By developing new systems and algorithms from ground up and optimizing existing software for modern hardware, QDX achieves large-scale molecular dynamics and quantum simulations with unmatched speed and scale. From small molecules to entire protein complexes, QDX makes quantum simulations pragmatic and relevant in applications such as drug discovery and materials science. QDX's cross-disciplinary team focuses on industrializing, specializing, and delivering on the promise of classical and quantum computational chemistry for a range of applications and industries. Initially focusing on drug discovery, QDX collaborates with researchers and companies on complex projects, providing unique insights and capabilities through large-scale computations, quantum simulations, proprietary high-quality quantum training data, AI, and custom software. QDX is a globally-minded company based in Singapore and Australia. For more information please visit www.qdx.co.
[2]
QDX Announces Collaboration with Prelude Therapeutics on Novel Oncology Programs
SINGAPORE, July 22, 2024 /PRNewswire/ -- QDX, a computational drug discovery company, today announced a collaboration with Prelude Therapeutics, a clinical-stage precision oncology company, targeting undisclosed, previously undrugged oncology targets. QDX integrates its world-leading quantum mechanical simulation technology, supercomputing, artificial intelligence, and deep drug discovery expertise to advance computational chemistry and drug discovery. Peggy Scherle, PhD, CSO of Prelude, commented: "Computational approaches to drug discovery are showing increasing promise. We are pleased to work with the talented team at QDX to leverage their blend of high-performance computing, quantum simulations, and AI on these historically challenging targets." Loong Wang, Co-Founder and CEO of QDX, stated: "We are thrilled to be working with the team at Prelude to help break new ground on these programs. This collaboration with Prelude exemplifies the kind of bespoke partnerships that QDX engages in across academia and industry, deploying our best-in-class quantum technology, our massively parallel supercomputing, and AI systems." Kelvin Neu, MD, Co-Founder and Chair of QDX, added: "The accomplished biology and chemistry teams at Prelude have been very productive, generating a pipeline of small molecules against important and often challenging oncology targets. QDX has built a powerful platform by thoughtfully integrating complementary disciplines, guided by the practical needs and challenges of novel drug discovery, with a particular focus on select traditionally difficult-to-crack areas. We are honored that Prelude has chosen QDX to support them on these challenging targets and look forward to a productive collaboration." About QDX QDX is a computational drug discovery company integrating quantum mechanical simulations, supercomputing, and artificial intelligence. By developing new systems and algorithms from ground up and optimizing existing software for modern hardware, QDX achieves large-scale molecular dynamics and quantum simulations with unmatched speed and scale. From small molecules to entire protein complexes, QDX makes quantum simulations pragmatic and relevant in applications such as drug discovery and materials science. QDX's cross-disciplinary team focuses on industrializing, specializing, and delivering on the promise of classical and quantum computational chemistry for a range of applications and industries. Initially focusing on drug discovery, QDX collaborates with researchers and companies on complex projects, providing unique insights and capabilities through large-scale computations, quantum simulations, proprietary high-quality quantum training data, AI, and custom software. QDX is a globally-minded company based in Singapore and Australia. For more information please visit www.qdx.co. SOURCE QDX Market News and Data brought to you by Benzinga APIs
Share
Share
Copy Link
QDX Technology and Prelude Therapeutics have announced a collaboration to develop novel oncology programs. The partnership aims to leverage QDX's AI-driven drug discovery platform to accelerate Prelude's cancer drug development efforts.
In a significant development for the field of oncology, QDX Technology and Prelude Therapeutics have announced a strategic collaboration aimed at advancing novel cancer treatment programs 1. This partnership brings together QDX's cutting-edge artificial intelligence (AI) drug discovery platform and Prelude's expertise in oncology drug development, potentially accelerating the path to new cancer therapies.
At the heart of this collaboration is QDX's proprietary AI-driven drug discovery platform. This advanced technology is designed to rapidly identify and optimize potential drug candidates, significantly reducing the time and cost typically associated with early-stage drug development 2. By applying this AI capability to Prelude's oncology programs, the partnership aims to streamline the drug discovery process and potentially bring innovative treatments to patients faster.
The collaboration will initially focus on multiple undisclosed oncology targets selected by Prelude Therapeutics 1. These targets represent areas of unmet medical need in cancer treatment, where new therapeutic approaches could potentially make a significant impact on patient outcomes. The partnership underscores both companies' commitment to pushing the boundaries of cancer research and treatment.
While specific financial details of the agreement have not been disclosed, the collaboration includes provisions for milestone payments and royalties to QDX based on the success of the programs 2. This structure aligns the interests of both companies and provides incentives for achieving key development and commercial milestones.
This collaboration between QDX and Prelude Therapeutics represents a growing trend in the pharmaceutical industry towards leveraging AI and machine learning in drug discovery. By combining QDX's technological prowess with Prelude's deep understanding of cancer biology and drug development, the partnership has the potential to accelerate the pace of innovation in oncology research 12.
As the collaboration progresses, it will be closely watched by industry observers and patients alike. Success in this venture could not only lead to new treatment options for cancer patients but also validate the role of AI in transforming the drug discovery landscape. The partnership between QDX and Prelude Therapeutics may well serve as a model for future collaborations in the biotech and pharmaceutical sectors.
Singapore's Quantum Engineering Programme (QEP) signs MoU with Quantinuum, granting researchers access to advanced quantum computers. This collaboration aims to boost quantum technology development and applications in Singapore.
2 Sources
2 Sources
Swiss pharmaceutical giant Roche collaborates with Singapore-based AI company Qritive to enhance cancer diagnostics worldwide using artificial intelligence, aiming to improve accuracy and efficiency in pathology.
2 Sources
2 Sources
Quantum-Si collaborates with NVIDIA to develop Proteus, a new proteomics platform, leveraging AI and accelerated computing to enhance single-molecule protein sequencing and analysis.
2 Sources
2 Sources
Exscientia, a leading AI-driven pharmatech company, has acquired full rights to a potential best-in-class CDK7 inhibitor for cancer treatment. The move has been met with positive analyst reactions and a buy rating.
3 Sources
3 Sources
Researchers at SMU have developed SmartCADD, an open-source tool that combines AI, quantum mechanics, and computer-assisted drug design to significantly speed up the drug discovery process.
4 Sources
4 Sources
The Outpost is a comprehensive collection of curated artificial intelligence software tools that cater to the needs of small business owners, bloggers, artists, musicians, entrepreneurs, marketers, writers, and researchers.
© 2025 TheOutpost.AI All rights reserved